Paper Contents
Abstract
This review examines the current state of antiretroviral therapy (ART) for HIV-infected children, highlighting recent advancements, ongoing challenges, and future directions. Despite significant progress in expanding access to pediatric ART globally, children continue to experience disparities in treatment coverage compared to adults. Current guidelines recommend immediate ART initiation for all HIV-infected children regardless of clinical or immunological status, with preference for integrase strand transfer inhibitor (INSTI)-based regimens Perpetration of these recommendations faces substantial walls including poor delectability of pediatric phrasings, complex administration procedures, and limited vacuity of child-friendly phrasings. Global treatment content for children reached roughly 57 by 2023, which remains vastly lower than the 77-content achieved in grown-ups. Recent developments include the preface of alternate- generation INSTIs similar as dolutegravir and bictegravir, which have been approved for youngish children and show bettered efficacity and tolerability. This review discusses the unique considerations in pediatric ART including age-specific dosing, experimental pharmacokinetics, adherence support strategies, and the operation of treatment failure. Addressing the patient gaps in pediatric HIV care requires innovative approaches to medicine expression, simplified treatment rules, and family- centered care models.
Copyright
Copyright © 2025 Bugubaeva Makhabat Mitalipovna. This is an open access article distributed under the Creative Commons Attribution License.
